Halofuginone: A novel antifibrotic therapy

General Pharmacology

Volumn 30, Issue 4, 1998, Pages 445-450

  Pines, M ^a   Nagler, A ^b  

^a VOLCANI CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cirrhosis; Collagen; Fibrosis; Graft versus host disease; Scleroderma

Indexed keywords

COLLAGEN TYPE 1; HALOFUGINONE;

COLLAGEN SYNTHESIS; DOSE RESPONSE; FIBROSIS; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; PERITONEUM ADHESION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SKIN FIBROSIS; TENDON SURGERY;

ADHESIONS; ANIMALS; COLLAGEN; FIBROSIS; HUMANS; LIVER CIRRHOSIS; PIPERIDINES; POSTOPERATIVE COMPLICATIONS; PROTEIN SYNTHESIS INHIBITORS; PULMONARY FIBROSIS; QUINAZOLINES; QUINAZOLINONES; SKIN;

EID: 0032054482     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00307-8     Document Type: Review

References (57)

1. Angel S., Weinberg Z. G., Polishuk O., Heit M., Plavnik I., Bartov I. A connection between a dietary coccidiostat and skin tears of female broiler chickens. Poult. Sci. 64:1985;294-296.
2. Bedalov A., Breault D. T., Sokolov B. P., Lichtler A. C., Bedalov I., Clark S. H., Mack K., Khillan J. S., Woody C. O., Kream B. E., Rowe D. Regulation other α1(I) collagen-producing cells in transgenic animals and cultured cells. J. Biol. Chem. 269:1994;4903-4909.
3. Boker K., Schwarting G., Kaule G., Gunzler V., Schmidt E. Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition of prolyl 4-hydroxylase. J. Hepatol. 13:1991;S35-S40.
4. Border W. A., Noble N. A. Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 331:1994;1286-1292.
5. Bornstein P. Regulation of expression of the α1(I) collagen gene. a critical appraisal of the role of the first intron Matrix Biol. 15:1996;3-10.
6. Bornstein P., Sage H. Structurally distinct collagen types. Annu. Rev. Biochem. 49:1980;957-1003.
7. Brenner D. A., Westwick J., Breindl M. Type I collagen gene regulation and molecular pathogenesis of cirrhosis. Am. J. Physiol. 264:1993;G589-G595.
8. Casas J. A., Subauste C. P., Alarcon G. S. A new promising treatment in systemic sclerosis. 5-fluorouracil Ann. Rheum. Dis. 46:1987;763-767.
9. Choi E. T., Callow A. D., Sehgal N. L., Brown D. M., Ryan U. S. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch. Surg. 130:1995;257-261.
10. Claman H. N., Jaffee B. D., Huff J. C., Clark R. A. F. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 94:1985;73-84.
11. Cunliffe C. J., Franklin T. J., Hales N. J., Hill G. B. Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analogue N-oxaloglycine and its derivates. J. Med. Chem. 35:1992;2652-2658.
12. Delany A. M., Brinckerhoff C. E. The synthetic retinoid (4-hydroxyphenyl) retinamide decreases collagen expression in vitro and in the tight-skin mouse. Arthritis Rheum. 36:1993;983-993.
13. Fleischmajer R., Olsen B. R., Kuhn K. Structure, molecular biology and pathology of collagens. Ann. NY Acad. Sci. 580:1990;1-64.
14. Friedman S. L. The cellular basis of hepatic fibrosis. Mechanism and treatment strategies. N. Engl. J. Med. 328:1993;1828-1835.
15. Friedman D. W., Boyd C. D., Mackenzie J. W., Norton P., Olson R. M., Deak S. B. Regulation of collagen gene expression in keloids and hypertrophic scars. J. Surg. Res. 55:1993;214-222.
16. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326:1992;242-245.
17. Granot I., Bartov I., Plavnik I., Wax E., Hurwitz S., Pines M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult. Sci. 70:1991;1559-1563. . a.
18. Granot I., Pines M., Plavnik I., Wax E., Hurwitz S., Bartov I. Skin tearing in broilers in relation to skin collagen. effect of sex, strain, and diet Poult. Sci. 70:1991;1928-1935. . b.
19. Granot I., Hurwitz S., Halevy O., Pines M. Halofuginone. an inhibitor of collagen type I synthesis Biochim. Biophys. Acta. 1156:1993;107-112.
20. Halevy O., Nagler A., Levi-Schaffer F., Genina O., Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients. effect of halofuginone Biochem. Pharmacol. 52:1996;1057-1063.
21. Hata R. I. Transfection of normal human skin fibroblasts with human α1(I) and α2(I) collagen gene constructs and evidence for their coordinate expression. Cell Biol. Int. 19:1995;735-741.
22. Karsenty G., de Crombrugghe B. Two different negative and one positive regulatory factors interact with a short promoter segment of the α1(I) collagen gene. J. Biol. Chem. 265:1990;9934-9942.
23. Keene D. R., Sakai L. Y., Bachinger H. P., Burgeson R. E. Type III collagen can be present on banded collagen fibrils regardless of fibril diameter. J. Cell. Biol. 105:1987;2393-2402.
24. Kershenobich D., Vargas F., Garcia-Tsao G., Tamayo R. P., Gent M., Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N. Engl. J. Med. 318:1988;1709-1713.
25. Khillan J. S., Li S. W., Prockop D. J. Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene. Proc. Natl. Acad. Sci. USA. 91:1994;6298-7302.
26. Kivirikko K. I. Collagens and their abnormalities in a wide spectrum of diseases. Ann. Med. 25:1993;113-126.
27. Kivirikko K. I., Myllyla R. Post-translational processing of procollagens. Ann. NY Acad. Sci. 460:1985;187-201.
28. Laptev A. V., Lu Z., Colige A., Prockop D. J. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA. Biochemistry. 33:1994;11033-11039.
29. Levi-Schaffer F., Nagler A., Slavin S., Knopov V., Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice. effect of halofuginone J. Invest. Dermatol. 106:1996;84-88.
30. Menzies D. Postoperative adhesions. their treatment and relevance in clinical practice Ann. R. Coll. Surg. Engl. 75:1993;147-153.
31. Monk B. J., Berman M. L., Montz F. J. Adhesions after extensive gynecologic surgery. clinical significance, etiology and prevention Am. J. Obstet. Gynecol. 170:1994;1396-1403.
32. Muriel P., Suarez O. R., Gonzalez P., Zuniga L. Protective effect of S-adenosyl-1-methionine on liver damage induced by biliary obstruction in rats. An histological, ultrastructural and biochemical approach. J. Hepatol. 21:1994;95-102.
33. Nagler A., Firman N., Feferman R., Cotev S., Pines M., Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am. J. Resp. Critical Care Med. 154:1996;1082-1086.
34. Nagler A., Miao H. Q., Eingorn H., Slavin S., Pines M., Genina O., Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc Biol. 17:1997;194-202.
35. Nagler A., Rivkind A. I., Raphael J., Levi-Schaffer F., Genina O., Lavelin I. and Pines M. (in press) Halofuginone - an inhibitor of collagen type I synthesis - prevents post-operation abdominal adhesions formation. Annals of Surgery.
36. Nelson P. R., Yamamura S., Kent K. C. Extracellular matrix proteins are potent agonists for human smooth muscle cell migration. J. Vasc. Surg. 24:1996;25-33.
37. Nyska M., Nyska A., Rivlin E., Porat S., Pines M., Shoshan S., Nagler A. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduced peritendinous fibrous adhesions following surgery. Connect. Tissue Res. 34:1996;97-103.
38. Palvin D., Lichtler A. C., Bedalov A., Kream B. E., Harrison J. R., Thomas H. F., Gronowicz G. A., Clark S. H., Woody C. O., Rowe D. W. Differential utilization of regulatory domains within the α1(I) collagen promoter in osseous and fibroblastic cells. J. Cell Biol. 116:1992;227-236.
39. Phan S. H. New strategies for treatment of pulmonary fibrosis. Thorax. 50:1995;415-421.
40. Pines M., Knopov V., Genina O., Lavelin I., Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 27:1997;391-398.
41. Polisson R. P., Gilkeson G. S., Pyun E. H., Pisetsky D. S., Smith E. A., Simon L. S. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis. effect on cutaneous fibrosis and interleukin 2 receptor levels J. Rheumatol. 23:1996;654-658.
42. Prockop D. J., Kivirikko K. I. Collagens. molecular biology, disease, and potentials for therapy Annu. Rev. Biochem. 64:1995;403-434.
43. Ramirez F., Di Liberto M. Complex and diversified regulatory programs control the expression of vertebrate collagen genes. FASEB J. 4:1990;1616-1623.
44. Rhodes K., Rippe R. A., Umezawa A., Nehls M., Brenner D. A., Breindl M. DNA methylation represses the murine alpha 1(I) collagen promoter by an indirect mechanism. Mol. Cell. Biol. 14:1994;5950-5960.
45. Rodemann P. H., Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother. Oncol. 35:1995;83-90.
46. Rodemann P. H., Binder A., Burger A., Guven N., Loffler H., Bamberg M. The underlying cellular mechanism of fibrosis. Kidney Int. 54:1996;S32-S36.
47. Ross R. The pathogenesis of atherosclerosis. a prospective for the 1990s Nature. 362:1993;801-809.
48. Salo T., Oikarinen K. S., Oikarinen A. I. Effect of phenytoin and nifedipine on collagen gene expression in human gingival fibroblasts. J. Oral Pathol. Med. 19:1990;404-407.
49. Siracusa L. D., Christner P., McGrath R., Mowers S. D., Nelson K. K., Jimenez S. A. The tight skin (Tsk) mutation in the mouse, a model for human fibrotic diseases, is tightly linked to the beta 2-microglobulin (B2m) gene on chromosome 2. Genomics. 17:1993;748-751.
50. Thompson J. P., Simkevich C. P., Holness M. A., Kang A. H., Raghow R. In vitro methylation of the promoter and enhancer of the proα1(I) collagen gene leads to its transcriptional inactivation. J. Biol. Chem. 266:1991;2549-2556.
51. Van der Rest M., Garrone R. Collagen family of proteins. FASEB J. 5:1991;2814-2823.
52. Vuorio T., Kahari V. M., Black C., Vuorio E. Expression of osteonectin, decorin, and transforming growth factor β1 genes in fibroblasts cultures from patients with systemic sclerosis and morphea. J. Rheumatol. 18:1991;247-251.
53. Weibel M. A., Manjo G. Peritoneal adhesions and their relationship to abdominal surgery. Am. J. Surg. 126:1973;345-353.
54. Yaffe H., Beyth U., Reinhartz T., Levij I. S. Foreign body granulomas in peritubal and periovarian adhesions. a possible cause for unsuccessful reconstructive surgery in fertility Fert. Steril. 33:1980;277-279.
55. Yeowell H. N., Ha V., Walker L. C., Murad S., Pinnell S. R. Characterization of a partial cDNA for lysyl hydroxylase from human skin fibroblasts; lysyl hydroxylase mRNAs are regulated differently by minoxidil derivatives and hydralazine. J. Invest. Dermatol. 99:1992;864-869.
56. Zhang K., Flanders K. C., Phan S. Cellular localization of transforming growth factor-β expression in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 147:1995;352-361. . a.
57. Zhang K., Garner W., Cohen L., Rodrigez J., Phan S. Increased types I and III collagen and transforming growth factor-β1 mRNA and protein in hypertrophic burn scar. J. Invest. Dermatol. 104:1995;750-754. . b.